Why the study?
Current therapeutic options for familial hypercholesterolemia remain relatively limited and only partially effective in lowering low-density lipoprotein cholesterol and modifying coronary heart disease risk.
Answers are grounded in this paper and cite their sources.
DNA- and RNA-based therapeutics represent a promising emerging approach to target the underlying genetic causes of familial hypercholesterolemia, potentially overcoming the limitations of conventional medications.
Familial hypercholesterolemia (FH) is a genetic disease that leads to elevated low-density lipoprotein cholesterol levels and risk of coronary heart disease. Current therapeutic options for FH remain relatively limited and only partially effective in both lowering low-density lipoprotein cholesterol and modifying coronary heart disease risk. The unique characteristics of nucleic acid therapies to target the underlying cause of the disease can offer solutions unachievable with conventional medications. DNA- and RNA-based therapeutics have the potential to transform the care of patients with FH. Recent advances are overcoming obstacles to clinical translation of nucleic acid-based medications, including greater stability of the formulations as well as site-specific delivery, making gene-based therapy for FH an alternative approach for treatment of FH.
No takes yet. Share an insight, caveat, or question.
Damase et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: